Plasma and urine pharmacokinetics of the dopamine agonist α-dihydroergocryptine in patients with hepatic dysfunction

International Journal of Clinical Pharmacology and Therapeutics

Volumn 39, Issue 2, 2001, Pages 67-74

  Althaus, M ^a   de Mey, C ^a   Ezan, E ^a   Ciecko Michalska, I ^a   Kostka Trabka, E ^a   Goszcz, A ^a   Retzow, A ^a  

^a ALK SCHERAX Arzneimittel GmbH   (Germany)

Author keywords

Hepatic dysfunction; Pharmacokinetics; dihydroergocryptine

Indexed keywords

ALCOHOL; ANTACID AGENT; BARBITURIC ACID DERIVATIVE; BROMOCRIPTINE; CIMETIDINE; CLOTRIMAZOLE; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DIHYDROERGOCRYPTINE; DIHYDROERGOTOXINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ERGOLINE DERIVATIVE; ERGOT DERIVATIVE; ERYTHROMYCIN; GLYCOPROTEIN P; GUANINE NUCLEOTIDE BINDING PROTEIN; KETOCONAZOLE; LIVER ENZYME; MULTIDRUG RESISTANCE PROTEIN; PHENOTHIAZINE DERIVATIVE; PHOSPHATE BINDING AGENT; POLYPROPYLENE; PROTON PUMP INHIBITOR; UNINDEXED DRUG; XANTHINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; COLLAPSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSFORMATION; DRUG URINE LEVEL; FEMALE; HEADACHE; HUMAN; KIDNEY CLEARANCE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAINTENANCE THERAPY; MALAISE; MALE; METABOLIC REGULATION; NAUSEA AND VOMITING; PLASMA; RADIOIMMUNOASSAY; REFERENCE VALUE; REGULATORY MECHANISM; SIDE EFFECT; TITRIMETRY; URINALYSIS; URINARY EXCRETION; XEROSTOMIA;

EID: 0035105366     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp39067     Document Type: Article

References (24)

1. In vitro identification of the cytochrome P-450 isoenzyme responsible for the metabolism of α-dihydroergocryptine
2. Alpha-dihydroergocryptine in Parkinson's disease: A multicentre randomized double-blind parallel-group study
3. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: Results of a multicentre, randomized, double-blind, placebo-controlled study
4. Relative bioequivalence of three oral forms of daverium: Capsules, tablets, oral drops. Study with a single dose of 20 mg in male and female volunteers
5. Highly sensitive and specific radioimmunoassays for dihydroergotoxine components in plasma
6. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol
7. Bio-equivalence study of α-dihydroergocryptine: Utility of metabolite evaluation
8. Bromocriptine transcriptionally activates the multidrug resistance gene (pgp2/mdr 1b) by a novel pathway
9. Pharmacokinetics of α-dihydroergokryptine in rats after intravenous and oral administration
10. Pharmacokinetics of α-dihydroergokryptine in monkeys after oral administration
11. Value of Doppler ultrasound parameters of portal vein and hepatic artery in the diagnosis of cirrhosis and portal hypertension
12. Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function
13. Pharmacocinétique de l'Hydergine chez le sujet agé
14. Interaction of ergot alkaloids and their combination (co-dergocrine) with α-adrenoceptors in the CNS
15. Dopamine receptor profile of co-dergocrine (Hydergine) and its components
16. Dihydroergocryptine in the treatment of Parkinson's disease: A six-month double-blind clinical trial
17. Metabolism study of dihydro-α-ergocryptine, 9, 10-[9,10-3H(N)] in rat and human hepatocyte cultures and rat, monkey, and human microsomes
18. Bromocriptine modulates P-glycoprotein function
19. High affinity of ergopeptides for cytochromes P450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine
20. La dihidroergocriptina in terapia associativa nel trattamento del morbo di Parkinson: Studio in doppio cieco versus bromocriptina
21. Pharmacokinetic and metabolism study in healthy volunteers after administration of single oral dose of 3H-α-dihydroergocryptine mesylate
22. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
23. Effects of several ergosines on adenylate cyclase activity in synaptosomal membranes of the bovine caudate nucleus
24. Pharmacokinetics and pharmacodynamics of α-dihydroergocriptine in humans: Single dose and steady state